Q-omics provides the consensus-scored SLC26A6 profile across patient tissues and cancer cell-line models. SLC26A6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC26A6 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, SLC26A6 RNA expression shows 19,098 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where SLC26A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC26A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC26A6 survival associations across molecular data types. SLC26A6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC26A6 RNA expression–survival associations across cancer types. High SLC26A6 expression shows unfavorable associations in KIRC, ACC, MESO, KICH, LIHC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC26A6 RNA expression.
This table summarizes SLC26A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC26A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC26A6 shows higher tumor expression in BLCA, HNSC, LIHC, LUAD, STAD and LUSC. The BLCA box plot shows higher SLC26A6 RNA expression in tumor versus normal tissue (log2 FC = +2.094, t-test p < 0.001).
This table shows molecular features associated with SLC26A6 in patient tissues and cancer cell lines. In patient samples, SLC26A6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC26A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
